HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments
Cancers · 29.03.2024 · 16 (7) · 1336
DOI: 10.3390/cancers16071336 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.03.2024. Verfasst von Magdalena K Scheck und 2 weiteren Autor:innen. Beteiligte Einrichtung: Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München, 81675 Munich, Germany. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite a decreasing incidence in Western countries, gastric cancer is among the most common cancer subtypes globally and is associated with one of the highest tumor-related mortality rates. Biomarkers play an increasing role in the treatment against gastric cancer. HER2 was one of the first biomarkers that found its way into clinical practice. Since the ToGA trial, trastuzumab has been part of first-line palliative chemotherapy in metastatic or unresectable gastric cancer. HER2-targeting agents, such as the tyrosine kinase inhibitor lapatinib, the antibody drug conjugate (ADC) trastuzumab-emtansine or dual HER2 inhibition (pertuzumab and trastuzumab), have been investigated in the second-line setting but led to negative study results. More recently, the ADC trastuzumab-deruxtecan was authorized after the failure of trastuzumab-based treatment. However, further improvements in HER2-directed therapy are required as resistance mechanisms and HER2 heterogeneity limit the existing treatment options. This review aims to give an overview of the current standard-of-care HER2-directed therapy in gastric cancer, as well as its challenges and future developments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München, 81675 Munich, Germany.
- Mannheim Cancer Center, Universitätsklinikum Mannheim, 68167 Mannheim, Germany.
ORCID-Profile: Magdalena K Scheck, Ralf D Hofheinz, Sylvie Lorenzen
Zitieren
APA
Scheck, M. K., Hofheinz, R. D., & Lorenzen, S. (2024). HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments. Cancers, 16(7), 1336. https://doi.org/10.3390/cancers16071336
Vancouver
Scheck MK, Hofheinz RD, Lorenzen S. HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments. Cancers. 2024;16(7):1336. doi:10.3390/cancers16071336
BibTeX
@article{Scheck2024,
author = {Scheck, Magdalena K and Hofheinz, Ralf D and Lorenzen, Sylvie},
title = {HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments},
journal = {Cancers},
year = {2024},
volume = {16},
number = {7},
pages = {1336},
doi = {10.3390/cancers16071336}
}
EUVIMED